Clinical Investigation| Volume 346, ISSUE 5, P381-384, November 2013

Helicobacter pylori Eradication Does Not Change Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor Binding Protein 3 Levels in Patients With and Without Precancerous Gastric Lesions



      Circulating insulin-like growth factor (IGF)-1 and IGF-binding protein (IGFBP)-3 levels in the serum of Helicobacter pylori (H pylori)-infected patients were investigated.


      The study subjects consisted of 54 patients with H pylori infection, and the control subjects included 27 patients without H pylori infection. There was no statistical difference in the age and sex distributions between the study and control groups. Pretreatment serum levels of IGF-1 and IGFBP-3 were studied in all the subjects, including the healthy controls. H pylori eradication was achieved with a triple drug regimen for 2 weeks, and 1 month after this treatment, the serum levels of IGF-1 and IGFBP-3 were measured. The post-treatment H pylori status by a second gastroscopy, antral histopathology and urea breath testing was tested.


      The pretreatment serum levels of IGF-1 and IGFBP-3 of the study and control groups were not found to be different (P>0.05). H pylori treatment was successful in 42 patients in whom both serum IGF-1 and IGFBP-3 levels decreased with treatment, but the difference was only significant for the serum IGF-1 levels (P: 0.04). There was no change in the serum levels of IGF-1 and IGFBP-3 in the 27 patients with precancereous gastric lesions before and after successful H pylori eradication.


      No supporting evidence of a major interaction between H pylori infection itself and H pylori-associated premalignant lesions with circulating IGFBP-3 levels could be shown. Nevertheless, successful eradication of this microorganism led to a statistically significant decrease in serum IGF-1 levels.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Khandwala H.M.
        • McCutcheon I.E.
        • Flyvbjerg A.
        • et al.
        The effects of insulin-like growth factors on tumorigenesis and neoplastic growth.
        Endocr Rev. 2000; 21: 215-244
        • Yi H.K.
        • Hwang P.H.
        • Yang D.H.
        • et al.
        Expression of the insulin-like growth factors (IGFs) and the IGF-binding proteins (IGFBPs) in human gastric cancer cells.
        Eur J Cancer. 2001; 37: 2257-2263
        • Zhang Z.W.
        • Newcomb P.V.
        • Moorghen M.
        • et al.
        Insulin-like growth factor binding protein-3: relationship to the development of gastric pre-malignancy and gastric adenocarcinoma (United Kingdom).
        Cancer Causes Control. 2004; 15: 211-218
        • Baricević I.
        • Nedić O.
        • Nikolić J.A.
        • et al.
        Circulating insulin-like growth factors in patients infected with Helicobacter pylori.
        Clin Biochem. 2004; 37: 997-1001
        • IARC M.F.
        Monographs on the Evaluation of Carcinogenic Risks to Humans, Vol 61.
        in: Schistosomes, Liver Flukes and Helicobacter Pylori. IARC, Lyon, Francee1994
        • Dixon F.R.C.
        • Path
        • Genta R.M.
        • et al.
        Classification and grading of gastritis: the updated Sydney system.
        Am J Surg Pathol. 1996; 20: 1161-1181
        • Ma J.
        • Pollak M.N.
        • Giovannucci E.
        • et al.
        Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.
        J Natl Cancer Inst. 1999; 91: 620-625
        • Chan J.M.
        • Stampfer M.J.
        • Giovannucci E.
        • et al.
        Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study.
        Science. 1988; 279: 563-566
        • Hankinson S.E.
        • Willett W.C.
        • Colditz G.A.
        • et al.
        Circulating concentrations of insulin-like growth factor-I and risk of breast cancer.
        Lancet. 1998; 351: 1393-1396
        • Yu H.
        • Spitz M.R.
        • Mistry J.
        • et al.
        Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
        J Natl Cancer Inst. 1999; 20: 151-156
        • Jones J.I.
        • Clemmons D.R.
        Insulin-like growth factors and their binding proteins: biological actions.
        Endocr Rev. 1995; 16: 3-34
        • Deal C.
        • Ma J.
        • Wilkin F.
        • et al.
        Novel promoter polymorphism in insulin-like growth factor-binding protein-3: correlation with serum levels and interaction with known regulators.
        J Clin Endocrinol Metab. 2001; 86: 1274-1280
        • Jernström H.
        • Deal C.
        • Wilkin F.
        • et al.
        Genetic and nongenetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in healthy premenopausal women.
        Cancer Epidemiol Biomarkers Prev. 2001; 10: 377-384
        • Harrela M.
        • Koistinen H.
        • Kaprio J.
        • et al.
        Genetic and environmental components of interindividual variation in circulating levels of IGF-I, IGF-II, IGFBP-1, and IGFBP-3.
        J Clin Invest. 1996; 98: 2612-2615
        • Taha A.S.
        • Beastall G.
        • Morton R.
        • et al.
        Insulin-like growth factor-I in Helicobacter Pylori gastritis and response to eradication using bismuth based triple therapy.
        J Clin Pathol. 1996; 49: 676-678
        • Abrahms J.A.
        • Wang T.C.
        Adenorcinoma and other tumors of the stomach.
        in: 9th ed. Sleisenger and Fordtran’s gastrointestinal and liver disease. Saunders Elsevier, Philadelphia (PA)2010: 887-906